Polymun was founded in 1992 by Prof. Hermann Katinger. It is a private company fully owned by the Katinger family. Revenues are generated by contract development and manufacturing as well as creating liposomal/LNP formats of drugs for contract partners. These revenues are invested in the proprietary product pipeline and the further development of technology platforms. The R&D projects and technologies are open for co-development and licensing. Polymun operates in accordance with current GMP guidelines and holds an Austrian production license for pharmaceuticals (§63 Austrian Pharmaceutical Law) thus meeting the EU requirements for drug manufacturing. The last inspection by the Austrian regulatory authority AGES on behalf of EMA has taken place in May 2021, the last inspection by FDA in October 2013.
COMPETENCE & SERVICES
The two core competences of Polymun are the development and manufacture of biopharmaceuticals using mammalian cell technology as well as Polymun's innovative liposome/LNP technology and expertise. Today, Polymun can apply this drug delivery platform to all kinds of pharmaceutically active ingredients. The industrial applicability in scale and price is a common focus throughout all projects and technologies.
STAFF
Polymun employs a team of about 100 dynamic and highly qualified scientists, technicians and support staff. 45% hold an academic title, mostly in natural sciences such as biotechnology, biology or chemistry. About 45% graduated from technical schools or colleges. Men and women are found equally in all positions. Polymun is also giving several of its employees the opportunity to perform their bachelor, master or doctor theses within the scope of the company. With quality and reliability as a pre-requisite basis, innovation and creativity are strongly encouraged at Polymun.
NETWORK
Polymun has close contacts to the Department of Biotechnology at the University of Natural Resources and Life Sciences, Vienna. The fruitful scientific dialog and the broad methodological competence are of mutual benefit.Polymun is partner in a project of the EU Framework Program Horizon 2020 (EAVI2020) as well as in the European Training Networks SECRETERS and BIOMOLMACS.
PARTNERS
Polymun′s customers and partners include renowned companies such as Takeda and Vogelbusch GmbH as well as non-profit organizations such as Imperial College London and the International AIDS Vaccine Initiative (IAVI).
